Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
theophylline + etofylline
- Development stage
- Unknown
- Lead developer
- Zydus Lifesciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
theophylline + etofylline is a fixed-dose combination bronchodilator consisting of two xanthine derivatives. Theophylline acts as a non-selective phosphodiesterase (PDE) inhibitor, which increases intracellular cAMP levels, and as a competitive antagonist at adenosine receptors, leading to the relaxation of bronchial smooth muscle. Etofylline (also known as etophylline or 7-(2-hydroxyethyl)theophylline) is a derivative of theophylline that is included to enhance the solubility of the formulation and provide synergistic bronchodilatory effects with potentially improved tolerability. This combination is primarily indicated for the management of obstructive airway diseases, including chronic asthma, chronic obstructive pulmonary disease (COPD), and apnea of prematurity. It is commonly manufactured by companies such as SiNi Pharma and Zydus Lifesciences, and is available in various dosage forms including oral syrups, tablets, and injections.
- Brand names
- DeriphyllinTheolairSlo-Bid
- Other names
- theophylline + etophyllineetofylline + theophylline7-(2-hydroxyethyl)theophylline + theophylline
02
Targets
ADORA2A (Adenosine A₂A Receptor)ADORA1 (Adenosine receptor A1 subtype)ADORA3 (Adenosine A3 receptor)HDAC (HDAC family)PDE3ADORA2B (Adenosine A2B receptor)PDE4 (Phosphodiesterase 4A1)
Beyond the preview
Go deeper on theophylline + etofylline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on theophylline + etofylline.